View Mobile Site

High court will review $6.8 million verdict against drug maker

    WASHINGTON — A drug manufacturer won Supreme Court review Friday of a $6.8 million verdict in the case of a woman whose arm had to be amputated after she was injected with one of its medications.
    A jury in Vermont awarded the money to Diana Levine, who sued Wyeth after she was injected with its Phenergan nausea medication. The drug was inadvertently injected into an artery, which was seriously damaged. Doctors later amputated her arm.
    Wyeth contends it should not have been subjected to the lawsuit because the company had the approval of the U.S. Food and Drug Administration for the warning label that accompanied the drug.
    In upholding that verdict, the Vermont Supreme Court said state regulators could require sterner warnings than their federal counterparts about a drug’s potential side effects. Federal labeling requirements ‘‘create a floor, not a ceiling’’ for state regulation, the state court said.
    Wyeth has said the company recommended a label change to the FDA, but the agency told it to keep the existing language.
    The court separately is considering two other cases in which companies say federal laws pre-empt lawsuits.
    The case is Wyeth v. Levine, 06-1249.

Interested in viewing premium content?

A subscription is required before viewing this article and other premium content.

Already a registered member and have a subscription?

If you have already purchased a subscription, please log in to view the full article.

Are you registered, but do not have a subscription?

If you are a registed user and would like to purchase a subscription, log in to view a list of available subscriptions.

Interested in becoming a registered member and purchasing a subscription?

Join our community today by registering for a FREE account. Once you have registered for a FREE account, click SUBSCRIBE NOW to purchase access to premium content.

Membership Benefits

  • Instant access to creating Blogs, Photo Albums, and Event listings.
  • Email alerts with the latest news.
  • Access to commenting on articles.

Please wait ...